Phaseline

Companies › Cellenkos

Cellenkos: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Neurology, Oncology, Other; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CK0804
Cryopreserved allogeneic T-regulatory cell product engineered to traffic to bone marrow
–Phase 1MyelofibrosisApr 2027
CK0803
Allogeneic, cord blood-derived T regulatory cells with neurotropic homing markers
–Phase 1Amyotrophic Lateral SclerosisMay 2027
CK0801
Cord blood-derived T-regulatory cell product
–Phase 1Bone Marrow DiseaseMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05423691CK0804Phase 1MyelofibrosisOncologyApr 2027
NCT05695521CK0803Phase 1Amyotrophic Lateral SclerosisNeurologyMay 2027
NCT03773393CK0801Phase 1Bone Marrow DiseaseOtherMay 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.